Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies

1214O - Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

Date

19 Sep 2020

Session

Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies

Presenters

Marie Wislez

Citation

Annals of Oncology (2020) 31 (suppl_4): S735-S743. 10.1016/annonc/annonc282

Authors

M. Wislez1, J. Mazieres2, A. Lavole3, G. Zalcman4, O. Carre5, T. Egenod6, R. Caliandro7, R. Gervais8, G. Jeannin9, O. Molinier10, M.A. Massiani11, A. Langlais12, F. Morin13, F. Le Pimpec Barthes14, L. Brouchet15, J. Assouad16, B. Milleron13, D. Damotte17, M. Antoine18, V. Westeel19

Author affiliations

  • 1 Pneumo-oncology, Hôpital Cochin, 75014 - Paris/FR
  • 2 Thoracic Oncology Department, CHU Toulouse - Hôpital Larrey, 31059 - Toulouse/FR
  • 3 Pneumology, Hopital Tenon, 75020 - Paris/FR
  • 4 Department Of Thoracic Oncology, Hôpital Bichat, 75018 - Paris/FR
  • 5 Pneumology, Clinique de l'Europe Amiens, 80000 - Amiens/FR
  • 6 Thoracic Oncology, Hopital Dupuytren, 87042 - Limoges/FR
  • 7 Pneumology, Institut Mutualiste Montsouris, 75014 - Paris/FR
  • 8 Pneumology, Centre Francois Baclesse, 14076 - Caen/FR
  • 9 Thoracic Oncology, Hôpital Gabriel Montpied, 63003 - Clermont-Ferrand/FR
  • 10 Pneumology, Centre Hospitalier Du Mans, 72037 - Le Mans/FR
  • 11 Medical Oncology, Hopital René Huguenin - Institut Curie, 92210 - Saint-Cloud/FR
  • 12 Biostatistics, French Cooperative Thoracic Intergroup, 75009 - Paris/FR
  • 13 Clinical Research Unit, French Cooperative Thoracic Intergroup, 75009 - Paris/FR
  • 14 Thoracic Surgery, Hôpital Européen George Pompidou, 75015 - Paris/FR
  • 15 Thoracic Oncology Department, Hôpital Larrey, 31059 - Toulouse/FR
  • 16 Thoracic Surgery, Hôpital Tenon, 75020 - Paris/FR
  • 17 Pathology, Hôpital Cochin, 75014 - Paris/FR
  • 18 Pathology, Hopital Tenon, 75020 - Paris/FR
  • 19 Pneumology, Hopital Jean Minjoz, 25030 - Besançon/FR
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1214O

Background

Preoperative immune checkpoint inhibitor therapy may be of benefit in early-stage NSCLC. This multicenter trial assesses the feasibility of neoadjuvant durvalumab.

Methods

Pts IB>4cm–IIIA, non N2 resectable NSCLC (TNM 8th edition) receive 3 courses of durvalumab 750 mg (days 1, 15, 29) then underwent resection, between day 2 and 14 after last infusion. Primary endpoint was % of complete surgical resection (R0); secondary endpoints safety, overall survival (OS), disease-free survival (DFS), time between first infusion and surgery, response rate (RECIST 1.1), major pathological response (MPR).

Results

50 pts included between April 2017 and August 2019. 46 eligible. 67.4% males, median age, 61 y; all ECOG PS 0-1; 98% smokers; 23 adenocarcinoma, 19 squamous; clinical stages IB/IIA/IIB/IIIA n = 5/13/27/1. Among the 46 operated pts, 9 had pneumonectomy, 31 lobectomy, 3 bilobectomy, and 3 an exploratory thoracotomy (2 pleural carcinosis; 1 esophageal invasion). Study was stopped because of an excess in 90-day postoperative mortality (4 deaths, 9%, 1 unknown (died at home); 2 acute respiratory failures; 1 tracheal fistula). 3 out of 4 deceased pts had cardiovascular comorbidities (3 arterial hypertensions; 1 peripheral arterial disease; 1 ischemic heart disease), or other (1 severe COPD; 1 diabetes). 41 pts were R0 (90%). There was no Grade 3-5 durvalumab related AEs. 4/46 pts had PR, 36 SD and 6 PD. Median time between first infusion and surgery was 37 (range: 29-46). Median OS and DFS was not reached; 18-m OS: 88.7% [95% CI: 74.9-95.1] 18-m RFS: 69.7% [95% CI: 53.2-81.3].

Conclusions

Enrollment was stopped because of excessive 90-day postoperative mortality. Deaths were due to postoperative complications possibly related to comorbidities and not to direct durvalumab toxicity. MPR rates and ongoing correlative analyses will be presented.

Clinical trial identification

NCT03030131.

Editorial acknowledgement

Legal entity responsible for the study

French Cooperative Thoracic Intergroup (IFCT).

Funding

AstraZeneca.

Disclosure

M. Wislez: Advisory/Consultancy: Boeringher Ingelheim; Speaker Bureau/Expert testimony: Boeringher Ingelheim; Advisory/Consultancy: Roche; Speaker Bureau/Expert testimony: Roche; Travel/Accommodation/Expenses: Roche; Non-remunerated activity/ies: Roche; Advisory/Consultancy: MSD; Speaker Bureau/Expert testimony: MSD; Travel/Accommodation/Expenses: MSD; Non-remunerated activity/ies: MSD; Advisory/Consultancy: BMS; Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy: AstraZeneca; Speaker Bureau/Expert testimony: AstraZeneca; Travel/Accommodation/Expenses: AstraZeneca; Speaker Bureau/Expert testimony: Amgen; Travel/Accommodation/Expenses: Pfizer; Research grant/Funding (self): BMS. J. Mazieres: Advisory/Consultancy: Roche; Research grant/Funding (institution): Roche; Advisory/Consultancy: AstraZeneca; Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: BMS; Research grant/Funding (institution): BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Hengruii; Advisory/Consultancy: Daiichi; Advisory/Consultancy: Boehringer; Advisory/Consultancy: Takeda. A. Lavole: Travel/Accommodation/Expenses: BMS. G. Zalcman: Honoraria (self): Pfizer; Research grant/Funding (institution): Roche; Advisory/Consultancy: BMS; Honoraria (self): BMS; Travel/Accommodation/Expenses: BMS; Honoraria (self): AstraZeneca; Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: MSD. O. Molinier: Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Tesaro; Travel/Accommodation/Expenses: Boehringer Ingelheim. M.A. Massiani: Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/Expenses: Elivie; Travel/Accommodation/Expenses: Amgen; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Boehringer Ingelheim; Travel/Accommodation/Expenses: AstraZeneca; Travel/Accommodation/Expenses: MSD. D. Damotte: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: AstraZeneca; Research grant/Funding (self): MedImmune; Honoraria (self): AbbVie; Travel/Accommodation/Expenses: AbbVie. M. Antoine: Honoraria (self): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca. V. Westeel: Honoraria (self): Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: MSD; Speaker Bureau/Expert testimony: BMS; Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Pfizer; Travel/Accommodation/Expenses: Boehringer Ingelheim; Travel/Accommodation/Expenses: BMS; Research grant/Funding (institution): BMS; Research grant/Funding (institution): MSD; Research grant/Funding (institution): Roche; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Fresenius; Research grant/Funding (institution): Merck-Serono. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings